Pacira BioSciences, Inc. (PCRX): Total Assets
$1.26B
As of 2025-12-31
$1.24B
As of 2026-06-30
-9.0%
3-year compound annual growth
-0.2%
5-year compound annual growth
+12.6%
10-year compound annual growth
| Period ended | Total Assets | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $1.26B | -18.6% | 2026-02-26, Balance as of period end |
| 2024-12-31 | $1.55B | -1.3% | 2026-02-26, Balance as of period end |
| 2023-12-31 | $1.57B | -6.4% | 2025-02-27, Balance as of period end |
| 2022-12-31 | $1.68B | -19.0% | 2024-02-29, Balance as of period end |
| 2021-12-31 | $2.08B | +62.8% | 2023-02-28, Balance as of period end |
| 2020-12-31 | $1.27B | +53.4% | 2022-02-28, Balance as of period end |
| 2019-12-31 | $831.07M | +20.6% | 2021-03-01, Balance as of period end |
| 2018-12-31 | $689.35M | +9.7% | 2020-02-21, Balance as of period end |
| 2017-12-31 | $628.37M | +60.5% | 2019-02-28, Balance as of period end |
| 2016-12-31 | $391.47M | +1.0% | 2018-02-28, Balance as of period end |
| 2015-12-31 | $387.74M | +18.9% | 2017-03-01, Balance as of period end |
| 2014-12-31 | $326.07M | +92.0% | 2016-02-25, Balance as of period end |
| 2013-12-31 | $169.82M | +51.6% | 2015-02-24, Balance as of period end |
| 2012-12-31 | $112.05M | -1.3% | 2014-02-25, Balance as of period end |
| 2011-12-31 | $113.49M | +70.5% | 2013-03-07, Balance as of period end |
| 2010-12-31 | $66.56M | n/a | 2012-03-27, Balance as of period end |
Total Assets at similar companies
| Company | Year ended | Total Assets | Change YoY |
|---|---|---|---|
| Pacira BioSciences, Inc. (PCRX) | 2025-12-31 | $1.26B | -18.6% |
| Amphastar Pharmaceuticals, Inc. (AMPH) | 2025-12-31 | $1.63B | +3.3% |
| Supernus Pharmaceuticals, Inc. (SUPN) | 2025-12-31 | $1.45B | +6.2% |
| Emergent BioSolutions Inc. (EBS) | 2025-12-31 | $1.32B | -5.1% |
| Corcept Therapeutics Inc (CORT) | 2025-12-31 | $836.65M | -0.5% |
| Kiniksa Pharmaceuticals International, plc (KNSA) | 2025-12-31 | $763.63M | +31.5% |
| Collegium Pharmaceutical, Inc (COLL) | 2025-12-31 | $1.66B | -0.4% |
| Ultragenyx Pharmaceutical Inc. (RARE) | 2025-12-31 | $1.53B | +1.9% |
| Axsome Therapeutics, Inc. (AXSM) | 2025-12-31 | $689.80M | +21.3% |
Compare PCRX, AMPH, SUPN, EBS side by side · Screen every company in Pharmaceutical Preparations ↗